CTOR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Citius Oncology Inc (CTOR) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has shown a positive price movement recently and technical indicators like MACD are slightly bullish, the lack of significant financial growth, poor earnings performance, absence of positive news catalysts, and no proprietary trading signals make it less compelling for immediate investment.
The MACD is slightly bullish with a positive histogram of 0.0108. RSI is neutral at 70.449, and moving averages are converging, indicating no strong trend. The stock is trading near its resistance level (R1: 1.224), which suggests limited immediate upside potential.
Recent price increase of 4.42% in the regular market and 1.69% in the post-market. MACD is slightly bullish.
No recent news or event-driven catalysts. Poor financial performance in the latest quarter with significant YoY declines in net income (-77.17%) and EPS (-80.65%). No significant hedge fund or insider trading activity. No recent congress trading data.
In Q4 2025, the company reported zero revenue growth (0.00% YoY). Net income dropped significantly to -$4,996,656 (-77.17% YoY), and EPS fell to -0.06 (-80.65% YoY). Gross margin remains at 0, showing no profitability.
No data on analyst ratings or price target changes.
